Eleftheria Zeggini is a leader in accelerating the translation of genomics into precision medicine. Her team identifies novel therapeutic targets and biomarkers for disease prognosis, management and prevention. Zeggini‘s research leverages big data in genetics and multi-omics for medically important human traits, such as osteoarthritis and type 2 diabetes. Her work generates insights into mechanisms of disease development and progression, shortening the path to clinical translation.
Eleftheria Zeggini joined Helmholtz Zentrum München in 2018. Previously, she had led a research group at the Human Genetics Faculty of the Wellcome Sanger Institute in Cambridge and before that worked at the Wellcome Centre for Human Genetics in Oxford. Zeggini obtained a BSc in Biochemistry and a PhD in Immunogenetics of Juvenile Arthritis from the University of Manchester. Most recently, she received a TUM Liesel Beckmann Distinguished Professorship at the TUM School of Medicine (Technical University of Munich/Klinikum Rechts der Isar).
About EMBO
EMBO is a leading organization in life sciences with approx. 1,800 highly esteemed members. The organization aims to promote excellence in life sciences in Europe and around the world. EMBO members support the community through their international collaborations and network and are actively involved in the organization’s projects, such as the evaluation of applications for EMBO funding, the mentoring of young scientists and by providing suggestions and feedback. New members of the organization are nominated and elected by its existing members in recognition of their outstanding scientific achievements.
Eleftheria Zeggini Awarded EMBO Membership
Awards & Grants
Computational Health
ITG
